Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.01.2023 | Case report

Durvalumab

Pneumonitis and autoimmune diabetes: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wen Y-P, et al. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. Medicine 101: No. 48, et al. Dec 2022. Available from: URL: http://doi.org/10.1097/MD.0000000000032076 Wen Y-P, et al. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report. Medicine 101: No. 48, et al. Dec 2022. Available from: URL: http://​doi.​org/​10.​1097/​MD.​0000000000032076​
Metadaten
Titel
Durvalumab
Pneumonitis and autoimmune diabetes: case report
Publikationsdatum
01.01.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-30703-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Diazoxide

Case report

Cefazolin